<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04151082</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0207</org_study_id>
    <secondary_id>NCI-2019-06735</secondary_id>
    <secondary_id>2019-0207</secondary_id>
    <nct_id>NCT04151082</nct_id>
  </id_info>
  <brief_title>High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors</brief_title>
  <official_title>Stop LCNP: High Dose Steroid Therapy for Late Radiation-Associated Lower Cranial Neuropathy: A Phase I/II Dose Finding Trial and Data Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effect and best dose of steroid therapy (prednisone or&#xD;
      methylprednisolone) in improving symptoms of late radiation-associated lower cranial&#xD;
      neuropathy in oropharyngeal cancer survivors. Steroid therapy with prednisone or&#xD;
      methylprednisolone may help to improve symptoms associated with late radiation-associated&#xD;
      lower cranial neuropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To establish feasibility and maximum tolerated dose (MTD) of steroid therapy that provides&#xD;
      symptomatic improvement in oropharyngeal cancer (OPC) survivors with late lower cranial&#xD;
      neuropathy (LCNP).&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To examine endpoints that may be sensitive to functional or symptomatic gains with steroid&#xD;
      therapy for late LCNP in OPC survivors by characterizing changes in symptoms, functional&#xD;
      status, quality of life (QOL), neurophysiology, and imaging studies after steroid therapy.&#xD;
&#xD;
      TERTIARY OBJECTIVE:&#xD;
&#xD;
      I. To establish a hypothesis-generating database of physiologic, functional, and&#xD;
      patient-reported outcomes (PROs) among head and neck cancer (HNC) survivors with late lower&#xD;
      cranial neuropathy treated with steroid therapy.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of steroid therapy followed by a phase II&#xD;
      study.&#xD;
&#xD;
      Patients receive prednisone orally (PO) (or by feeding tube) once daily (QD) on days 1-5 and&#xD;
      then taper off over 2 weeks or methylprednisolone intravenously (IV) over 1 hour on days 1-5&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MD Anderson Symptom Inventory - Head and Neck (MDASI-HN) top 5 mean</measure>
    <time_frame>Baseline up to 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in tongue innervation on electromyography (EMG) findings</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>EMG scores are based on a 4-point denervation potentials grade with '0' being 'none' and '4' being 'full interference patterns of potentials'.&#xD;
Nerve conduction study (NCS) scores are based on a 4-point scale ranging from 'none' (best) to 'severely prolonged' or 'severely reduced' (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in dynamic imaging grade of swallowing toxicity (DIGEST) scores</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>1. DIGEST scores are rated on a 0-4 scale from 0 (best) to 4 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in maximum isometric lingual strength (MILS) and lingual range of motion (LROM)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>MILS scores are rated on continuous scale from 0 (worst) to 100 (best).&#xD;
LROM scores are rated on an ordinal scale from 0 (worst) to 100 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in patient reported outcomes (PRO) on MD Anderson Dysphagia Inventory (MDADI), Performance Status Scale for Head and Neck (PSS-HN), or EuroQOL (EQ-5D)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>MDADI scores are rated on a continuous scale from 20 (worst) to 100 (best).&#xD;
Diet, eating, and speech subscales of PSS-HN are rated on an ordinal scale from 0 (worst) to 100 (best).&#xD;
EQ-5D is rated on a continuous scale from 0 (worst) to 100 (best).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cranial Nerve Disorder</condition>
  <condition>Head and Neck Carcinoma</condition>
  <condition>Oropharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Supportive care (steroid therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive prednisone PO (or by feeding tube) QD on days 1-5 and then taper off over 2 weeks or methylprednisolone IV over 1 hour on days 1-5 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Supportive care (steroid therapy)</arm_group_label>
    <other_name>Adlone</other_name>
    <other_name>Caberdelta M</other_name>
    <other_name>DepMedalone</other_name>
    <other_name>Depo Moderin</other_name>
    <other_name>Depo-Nisolone</other_name>
    <other_name>Duralone</other_name>
    <other_name>Emmetipi</other_name>
    <other_name>Esametone</other_name>
    <other_name>Firmacort</other_name>
    <other_name>Medlone 21</other_name>
    <other_name>Medrate</other_name>
    <other_name>Medrol</other_name>
    <other_name>Medrol Veriderm</other_name>
    <other_name>Medrone</other_name>
    <other_name>Mega-Star</other_name>
    <other_name>Meprolone</other_name>
    <other_name>Methylprednisolonum</other_name>
    <other_name>Metilbetasone Solubile</other_name>
    <other_name>Metrocort</other_name>
    <other_name>Metypresol</other_name>
    <other_name>Metysolon</other_name>
    <other_name>Predni-M-Tablinen</other_name>
    <other_name>Prednilen</other_name>
    <other_name>Radilem</other_name>
    <other_name>Sieropresol</other_name>
    <other_name>Solpredone</other_name>
    <other_name>Summicort</other_name>
    <other_name>Urbason</other_name>
    <other_name>Veriderm Medrol</other_name>
    <other_name>Wyacort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Supportive care (steroid therapy)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>Perrigo Prednisone</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Rayos</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Supportive care (steroid therapy)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Supportive care (steroid therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  INCLUSION CRITERIA FOR CLINICAL TRIAL: Disease free adult survivors of oropharyngeal&#xD;
             cancer&#xD;
&#xD;
          -  INCLUSION CRITERIA FOR CLINICAL TRIAL: Treated with radiotherapy &gt;= 2 years post&#xD;
             treatment (disease status per surveillance imaging and clinical surveillance)&#xD;
&#xD;
          -  INCLUSION CRITERIA FOR CLINICAL TRIAL: Late radiation-associated lower cranial&#xD;
             neuropathy of XII with or without X nerve (LCNP cases will be considered&#xD;
             therapy-related when imaging, physical examination, and/or biopsy fail to demonstrate&#xD;
             structural or malignant source)&#xD;
&#xD;
          -  INCLUSION CRITERIA FOR CLINICAL TRIAL: Willing and able to return for assessment&#xD;
             post-steroid therapy&#xD;
&#xD;
          -  INCLUSION CRITERIA FOR CLINICAL TRIAL: Able to complete symptom survey (MD Anderson&#xD;
             Symptom Inventory - Head and Neck [MDASI-HN]) in validated languages: English,&#xD;
             simplified Chinese, Filipino, Greek, Japanese, Korean, Russian, Spanish, Taiwanese&#xD;
&#xD;
          -  INCLUSION CRITERIA FOR REGISTRY: Disease-free adult survivors of head and neck cancer&#xD;
&#xD;
          -  INCLUSION CRITERIA FOR REGISTRY: &gt;= 2 years post treatment (disease status per&#xD;
             surveillance imaging and clinical surveillance)&#xD;
&#xD;
          -  INCLUSION CRITERIA FOR REGISTRY: Late lower cranial neuropathy of XII with or without&#xD;
             X nerve (LCNP cases will be considered therapy-related when imaging, physical&#xD;
             examination, and/or biopsy fail to demonstrate structural or malignant source)&#xD;
&#xD;
          -  INCLUSION CRITERIA FOR REGISTRY: Able to complete symptom survey (MDASI-HN) in&#xD;
             validated languages: English, simplified Chinese, Filipino, Greek, Japanese, Korean,&#xD;
             Russian, Spanish, Taiwanese&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR CLINICAL TRIAL: Uncontrolled diabetes&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR CLINICAL TRIAL: Uncontrolled hypertension (systolic &gt; 160;&#xD;
             diastolic &gt; 90)&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR CLINICAL TRIAL: Known gastrointestinal ulcer&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR CLINICAL TRIAL: History of psychosis&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR CLINICAL TRIAL: Pregnant women&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR CLINICAL TRIAL: Untreated or treatment refractory obstructive&#xD;
             pharyngoesophageal stricture&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR CLINICAL TRIAL: Known history or diagnosis of bipolar disorder&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR CLINICAL TRIAL: History of surgery near hypoglossal nerve path&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR REGISTRY: Uncontrolled diabetes&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR REGISTRY: Uncontrolled hypertension (systolic &gt; 160; diastolic&#xD;
             &gt; 90)&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR REGISTRY: Known gastrointestinal ulcer&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR REGISTRY: History of psychosis&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR REGISTRY: Pregnant women&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR REGISTRY: Untreated or treatment refractory obstructive&#xD;
             pharyngoesophageal stricture&#xD;
&#xD;
          -  EXCLUSION CRITERIA FOR REGISTRY: Known history or diagnosis of bipolar disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine A Hutcheson</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine A Hutcheson</last_name>
    <phone>713-792-6513</phone>
    <email>karnold@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine A. Hutcheson</last_name>
      <phone>713-792-6920</phone>
      <email>karnold@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Katherine A. Hutcheson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cranial Nerve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

